BioNexus Gene Lab Statistics
Total Valuation
BGLC has a market cap or net worth of $5.75 million. The enterprise value is $2.19 million.
Important Dates
The next estimated earnings date is Tuesday, June 3, 2025.
| Earnings Date | Jun 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BGLC has 1.80 million shares outstanding. The number of shares has decreased by -67.09% in one year.
| Current Share Class | 1.80M |
| Shares Outstanding | 1.80M |
| Shares Change (YoY) | -67.09% |
| Shares Change (QoQ) | +899.94% |
| Owned by Insiders (%) | 30.98% |
| Owned by Institutions (%) | 0.88% |
| Float | 1.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.73 |
| Forward PS | n/a |
| PB Ratio | 8.42 |
| P/TBV Ratio | 0.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.19, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.19 |
| Quick Ratio | 3.44 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -108.47 |
Financial Efficiency
Return on equity (ROE) is -24.75% and return on invested capital (ROIC) is -16.58%.
| Return on Equity (ROE) | -24.75% |
| Return on Assets (ROA) | -14.05% |
| Return on Invested Capital (ROIC) | -16.58% |
| Return on Capital Employed (ROCE) | -29.30% |
| Revenue Per Employee | $308,862 |
| Profits Per Employee | -$70,597 |
| Employee Count | 30 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 7.09 |
Taxes
| Income Tax | -16,574 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.27% in the last 52 weeks. The beta is 1.72, so BGLC's price volatility has been higher than the market average.
| Beta (5Y) | 1.72 |
| 52-Week Price Change | -38.27% |
| 50-Day Moving Average | 2.79 |
| 200-Day Moving Average | 3.43 |
| Relative Strength Index (RSI) | 54.72 |
| Average Volume (20 Days) | 100,521 |
Short Selling Information
The latest short interest is 50,545, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 50,545 |
| Short Previous Month | 291,486 |
| Short % of Shares Out | 2.81% |
| Short % of Float | 4.08% |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, BGLC had revenue of $9.27 million and -$2.12 million in losses. Loss per share was -$1.14.
| Revenue | 9.27M |
| Gross Profit | 1.27M |
| Operating Income | -2.32M |
| Pretax Income | -2.64M |
| Net Income | -2.12M |
| EBITDA | -2.21M |
| EBIT | -2.32M |
| Loss Per Share | -$1.14 |
Full Income StatementBalance Sheet
The company has $3.60 million in cash and $216,427 in debt, giving a net cash position of $3.38 million or $1.88 per share.
| Cash & Cash Equivalents | 3.60M |
| Total Debt | 216,427 |
| Net Cash | 3.38M |
| Net Cash Per Share | $1.88 |
| Equity (Book Value) | 7.77M |
| Book Value Per Share | 0.43 |
| Working Capital | 4.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.02 million and capital expenditures -$214,096, giving a free cash flow of -$3.24 million.
| Operating Cash Flow | -3.02M |
| Capital Expenditures | -214,096 |
| Free Cash Flow | -3.24M |
| FCF Per Share | -$1.80 |
Full Cash Flow StatementMargins
Gross margin is 13.68%, with operating and profit margins of -25.05% and -22.86%.
| Gross Margin | 13.68% |
| Operating Margin | -25.05% |
| Pretax Margin | -23.04% |
| Profit Margin | -22.86% |
| EBITDA Margin | -23.85% |
| EBIT Margin | -25.05% |
| FCF Margin | n/a |